Zhengye Biotechnology Holding Ltd
ZYBT Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- Zhengye Biotechnology Holding Ltd had $16.2M of revenue in fiscal 2025, down 37.5% on the year before.
- Its operating margin was −60.6%, down 69.4 pts: of every 100 in sales, about −61 is left after running the business.
- Zhengye Biotechnology Holding Ltd lost $9.7M in fiscal 2025.
- Free cash flow was $1.7M in fiscal 2025, 10.6% of revenue.
- Zhengye Biotechnology Holding Ltd owes $3.3M more than it holds in cash.
Market cap
—
P/E
—
Revenue
$16.2M
Net income
−$9.7M
Free cash flow
$1.7M
Operating margin
−60.6%
Zhengye Biotechnology Holding Ltd in 30 seconds · fiscal 2025
Are sales growing?
−37.5%
No. Sales fell 37.5% last year.
Does it make a profit?
−60.0%
No. It lost money last year.
Does profit turn into cash?
10.6%
Yes. 10.6% of sales ends up as free cash.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
What Zhengye Biotechnology Holding Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 28, 2026
- Legal name
- Zhengye Biotechnology Holding Ltd
- CIK
- 0001975641
Zhengye Biotechnology Holding Ltd · ZYBT
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $38.7M | $29.9M | $25.9M | $16.2M |
| Revenue growth | — | −22.7% | −13.3% | −37.5% |
| Gross margin | 56.8% | 55.5% | 49.0% | 20.5% |
| Operating margin | 25.3% | 21.3% | 8.8% | −60.6% |
| Net income | $6.9M | $4.4M | $1.6M | −$9.7M |
| Net margin | 18.0% | 14.9% | 6.1% | −60.0% |
| Diluted EPS | $0.15 | $0.10 | $0.03 | — |
| Cash | ||||
| Cash from operations | $2.6M | $6.8M | $5.7M | $1.9M |
| Capital expenditure | $4.1M | $1.0M | $1.9M | $0.1M |
| Free cash flow | −$1.5M | $5.8M | $3.8M | $1.7M |
| FCF margin | −3.8% | 19.3% | 14.7% | 10.6% |
| Dividends paid | $3.2M | $5.6M | $2.2M | — |
| Share count change | — | 0.0% | 0.0% | 3.7% |
| Debt and strength | ||||
| Cash and short-term investments | $1.4M | $2.3M | $2.7M | $7.4M |
| Debt incl. finance leases | — | $12.6M | $11.8M | $10.7M |
| Shareholders' equity | $51.7M | $38.4M | $38.9M | $35.7M |
| Net debt / EBITDA | — | 1.1x | 1.6x | — |
| Current ratio | — | 1.3x | 1.3x | 1.1x |
| Interest coverage | 23.2x | 10.2x | 4.1x | −20.7x |
| Returns and quality | ||||
| Return on capital | — | 11.2% | 4.5% | −19.9% |
| Return on equity | 13.4% | 9.9% | 4.1% | −26.0% |
| Return on tangible equity | 13.4% | 12.3% | 4.3% | −33.5% |
| Piotroski F-score | — | — | 6 | 3 |
| Altman Z'' | — | 3.2 | 3.2 | 1.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Zhengye Biotechnology Holding Ltd · ZYBT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001975641). Data updated October 24, 2026. Filed in CNY under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.